XOMA Royalty Corp — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 95/100
What the filing says
Ligand Pharmaceuticals (NASDAQ: LGND) completed its acquisition of XOMA Royalty Corporation on July 14, 2026, announced April 27, 2026. XOMA Royalty shareholders received $39.00 per share in cash plus one CVR per share entitling holders to 75% of net proceeds from pending litigation. XOMA Royalty common stock delisted from Nasdaq.
Why this rating
Acquisition eliminates the company as independent entity—existential event for XOMA shareholders. Relative to $167.8M market cap, represents full liquidity event at specified price.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.